4.8 Review

Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches

期刊

FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.762315

关键词

Mycobacterium tuberculosis; tuberculosis; systems biology; macrophage; omic technology

资金

  1. Biotechnology and Biological Sciences Research Council (BBSRC) [BB/V010611/1]
  2. BBSRC [BB/V010611/1] Funding Source: UKRI

向作者/读者索取更多资源

Tuberculosis is a devastating infectious disease that kills over a million people annually, with increasing challenges of multi and extensively drug resistant strains. Host-pathogen interactions, metabolic cross talk, and advancements in systems-based omic technologies play critical roles in TB research and offer promising interventions for anti-TB therapies.
Tuberculosis (TB) is a devastating infectious disease that kills over a million people every year. There is an increasing burden of multi drug resistance (MDR) and extensively drug resistance (XDR) TB. New and improved therapies are urgently needed to overcome the limitations of current treatment. The causative agent, Mycobacterium tuberculosis (Mtb) is one of the most successful pathogens that can manipulate host cell environment for adaptation, evading immune defences, virulence, and pathogenesis of TB infection. Host-pathogen interaction is important to establish infection and it involves a complex set of processes. Metabolic cross talk between the host and pathogen is a facet of TB infection and has been an important topic of research where there is growing interest in developing therapies and drugs that target these interactions and metabolism of the pathogen in the host. Mtb scavenges multiple nutrient sources from the host and has adapted its metabolism to survive in the intracellular niche. Advancements in systems-based omic technologies have been successful to unravel host-pathogen interactions in TB. In this review we discuss the application and usefulness of omics in TB research that provides promising interventions for developing anti-TB therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据